{"title":"利用检测无处不在突变的开关促进溶瘤载体复制","authors":"Michael A. Renteln","doi":"10.2174/1573394719666230502110244","DOIUrl":null,"url":null,"abstract":"\n\nMost existing cancer therapies negatively affect normal tissue as well as cancerous tissue.\nA potentially effective strategy for treating cancer that precludes off-target damage and could be an\noption for most patients would involve targeting one or more mutations that are ubiquitous in the\ngiven patient’s tumor(s). To effect this strategy, one would employ multi-region sequencing of a patient’s primary tumor and metastases to seek out mutations that are shared between all or at least\nmost regions. Once the target or targets are known, one would ideally rapidly generate a molecular\nswitch for at least one of said ubiquitous mutations that can distinguish the mutated DNA, RNA, or\nprotein from the wild-type version and subsequently trigger a therapeutic response. I propose that\nthe therapeutic response involve the replication of an oncolytic virus or intracellular bacterium, as\nany mutation can theoretically be detected by a vector that enters the cell - and automatic propagation could be very helpful. Moreover, the mutation “signal” can be easily enhanced through transcriptional and translational (if the target is an intracellular protein) enhancement. Importantly, RNA\nmay make the best target for the molecular switches in terms of amplification of the signal and ease\nof targeting.\n","PeriodicalId":43754,"journal":{"name":"Current Cancer Therapy Reviews","volume":" ","pages":""},"PeriodicalIF":0.4000,"publicationDate":"2023-05-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Promoting oncolytic vector replication with switches that detect ubiquitous mutations\",\"authors\":\"Michael A. Renteln\",\"doi\":\"10.2174/1573394719666230502110244\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"\\n\\nMost existing cancer therapies negatively affect normal tissue as well as cancerous tissue.\\nA potentially effective strategy for treating cancer that precludes off-target damage and could be an\\noption for most patients would involve targeting one or more mutations that are ubiquitous in the\\ngiven patient’s tumor(s). To effect this strategy, one would employ multi-region sequencing of a patient’s primary tumor and metastases to seek out mutations that are shared between all or at least\\nmost regions. Once the target or targets are known, one would ideally rapidly generate a molecular\\nswitch for at least one of said ubiquitous mutations that can distinguish the mutated DNA, RNA, or\\nprotein from the wild-type version and subsequently trigger a therapeutic response. I propose that\\nthe therapeutic response involve the replication of an oncolytic virus or intracellular bacterium, as\\nany mutation can theoretically be detected by a vector that enters the cell - and automatic propagation could be very helpful. Moreover, the mutation “signal” can be easily enhanced through transcriptional and translational (if the target is an intracellular protein) enhancement. Importantly, RNA\\nmay make the best target for the molecular switches in terms of amplification of the signal and ease\\nof targeting.\\n\",\"PeriodicalId\":43754,\"journal\":{\"name\":\"Current Cancer Therapy Reviews\",\"volume\":\" \",\"pages\":\"\"},\"PeriodicalIF\":0.4000,\"publicationDate\":\"2023-05-02\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Current Cancer Therapy Reviews\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.2174/1573394719666230502110244\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q4\",\"JCRName\":\"ONCOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Current Cancer Therapy Reviews","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.2174/1573394719666230502110244","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"ONCOLOGY","Score":null,"Total":0}
Promoting oncolytic vector replication with switches that detect ubiquitous mutations
Most existing cancer therapies negatively affect normal tissue as well as cancerous tissue.
A potentially effective strategy for treating cancer that precludes off-target damage and could be an
option for most patients would involve targeting one or more mutations that are ubiquitous in the
given patient’s tumor(s). To effect this strategy, one would employ multi-region sequencing of a patient’s primary tumor and metastases to seek out mutations that are shared between all or at least
most regions. Once the target or targets are known, one would ideally rapidly generate a molecular
switch for at least one of said ubiquitous mutations that can distinguish the mutated DNA, RNA, or
protein from the wild-type version and subsequently trigger a therapeutic response. I propose that
the therapeutic response involve the replication of an oncolytic virus or intracellular bacterium, as
any mutation can theoretically be detected by a vector that enters the cell - and automatic propagation could be very helpful. Moreover, the mutation “signal” can be easily enhanced through transcriptional and translational (if the target is an intracellular protein) enhancement. Importantly, RNA
may make the best target for the molecular switches in terms of amplification of the signal and ease
of targeting.
期刊介绍:
Current Cancer Therapy Reviews publishes frontier reviews on all the latest advances in clinical oncology, cancer therapy and pharmacology. The journal"s aim is to publish the highest quality review articles dedicated to clinical research in the field. The journal is essential reading for all researchers and clinicians in cancer therapy.